ArticleESMO open2026
Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab.
N Savion-Gaiger et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.